In this article, we will discuss Palonosetron Clinical Trials Effect (Liver). So, let’s get started.
Liver: < 1%: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes occurred predominantly in patients receiving highly emetogenic chemotherapy.